Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07685275

Real-Time Mass Spectrometry Breath Analysis for the Investigation of Respiratory Tract Infections

Lower respiratory tract infections (LRTIs) remain a major global health burden, with diagnosis often challenged by clinical heterogeneity, overlapping symptoms, difficulty in obtaining quality biological specimens and limitations of conventional microbiological testing. Exhaled breath contains thousands of volatile organic compounds (VOCs), arising from both host metabolism and microbial activity, and provides a non-invasive window into the metabolic landscape of infection. Emerging evidence from in vitro studies, animal models, and clinical investigations supports the existence of pathogen-specific VOC signatures. However, most published studies have relied on offline methods, such as gas chromatography-mass spectrometry (GC-MS), and robust proof-of-concept for real-time, bedside analysis in diverse, real-world populations is lacking. Proton transfer reaction-mass spectrometry (PTR-MS) offers rapid, quantitative, and non-invasive assessment of breath VOCs in both spontaneously breathing and mechanically ventilated patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

1 month and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital Raymond Poincaré, Garches, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged > 1 month, either spontaneously breathing or intubated and mechanically ventilated
  • Having suspected lower respiratory tract infection (dyspnea or tachypnea or cough or sputum production or fever or decreased breath sounds on auscultation or any other suspicious diagnostic test (imaging, blood analysis)) or previously documented chronic airway colonization
  • Willing to provide informed consent and affiliated with a health insurance system

Exclusion criteria

  • Patients or representative unable to provide informed consent
  • Persons under guardianship or curatorship or persons deprived of liberty

Treatment and study plan

Breath analysis

Diagnostic Test

breath sampling and collection and analysis (microscopic analysis, cultures and syndromic panel of a respiratory sample

Primary outcomes

  1. Infection test

    Time frame: Day 0

    Breath VOC signature for patient categorical classification of LRTI (infection / colonization / none)

Secondary outcomes

  1. Pathogen class test

    Time frame: Day 0

    Breath VOC signature differentiating bacterial and viral infections

  2. Pathogen ID test

    Time frame: Day

    Breath VOC signature differentiating major respiratory pathogens

  3. Diagnostic performance

    Time frame: Day 0

    Sensitivity, specificity, negative predictive value, positive predictive value, area under the ROC curve, accuracy of each test compared to reference standards

  4. Antimicrobial susceptibility test

    Time frame: Day 0

    Breath VOC signature differentiating susceptibility and resistance of a given pathogen to a given antibiotic (exploratory outcome).

Study contacts

Contact information is provided by the study sponsor or research team.

Stanislas Grassin Delyle

CONTACT

[email protected]

+33 1 46 25 73 93

Virginie Guitard

CONTACT

[email protected]

+33 1 46 25 73 88

Sponsors and collaborators

Lead sponsor

Hopital Foch

Other

Registry information

Acronym: Respire

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 6, 2026
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.